Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals is a biopharmaceutical company that pioneered the commercial development of RNA interference (RNAi) therapeutics — a class of medicines that work by "silencing" specific genes responsible for causing or contributing to disease. Rather than treating symptoms downstream, RNAi therapies target the messenger RNA that instructs cells to produce disease-causing proteins, addressing conditions closer to their genetic source.

The company's focus has centered on rare and genetically defined diseases, including hereditary transthyretin-mediated amyloidosis (hATTR), acute hepatic porphyria, and certain metabolic and cardiovascular conditions. These are often serious, progressive disorders where treatment options have historically been limited, and where a targeted molecular approach can meaningfully change the course of the disease.

Because Alnylam's products are prescription specialty therapeutics, they are prescribed and managed under the care of a physician — frequently a specialist familiar with the specific condition being treated. Many of these medicines are administered by injection or infusion and are handled through specialty pharmacy channels, with dosing schedules and monitoring determined by the treating clinician. If you have questions about eligibility, dosing, or patient support programs, your prescriber and pharmacist are the best resources.

At Honest Medical, we organize products by manufacturer to make it easier to locate the specific brand your provider has recommended. To explore offerings from other manufacturers, you can browse related brands such as Amneal Pharmaceuticals, Alembic Pharmaceuticals, and Altaire Pharmaceuticals. Always confirm any medication with your healthcare provider before beginning or changing a treatment plan.